March 4, 2020 – Shore Capital Partners (“Shore”), a Chicago-based private equity firm focused on microcap investments within the Healthcare and Food and Beverage industries, is pleased to announce the sale of its autism services portfolio company, Florida Autism Center / Fusion Autism Center (“FAC”), to BlueSprig Pediatrics (“BlueSprig”), a leading Houston, Texas based provider of autism services.

Shore Capital partnered with FAC founder Chryssy Moor’s four locations in 2015 with a goal of building the leading autism services platform in the southeast. Led by Chief Executive Officer Kristy Rohwedder, the team at FAC has evolved from its entrepreneurial beginnings into a rapidly growing enterprise, supported by highly scalable corporate infrastructure and a best in class leadership team. FAC is recognized industry wide as a market leader in the southeast with 52 total locations across Florida and Georgia. During the course of the partnership, Shore and the FAC management team have executed a repeatable de novo growth plan that has allowed the Company to scale rapidly in order to bring best-in-class autism services to as many clients as possible.

“We are pleased to have partnered with Kristy and Chryssy to build FAC into one of the leading autism services providers in the country,” said John Hennegan, co-founder of Shore Capital. “FAC demonstrates what is possible when clinically and operationally focused executives and investment professionals collaborate to build a business that provides desperately needed services into an attractive end market.

“Our goal has always been to increase the availability of our valuable services, so we can continue to positively impact the lives of children and families, and our partnership with BlueSprig will only increase our reach. We believe both organizations share an absolute commitment to providing the highest quality clinical services and that our values and philosophies are a wonderful fit,” said Kristy Rohwedder, CEO of FAC. “Shore’s operational oversight and financial support coupled with our management’s industry and clinical expertise helped facilitate the platform’s rapid expansion and we are excited to begin our partnership with BlueSprig to fuel the next phase of growth for FAC.”

The transaction closed on March 4, 2020. Terms of the transaction are not disclosed. Cain Brothers, a division of KeyBanc Capital Markets, provided M&A advisory services and Winston & Strawn provided legal advice to Shore Capital and FAC.

September 19, 2019 ‐ Founded in 1987 by Steve Marks and Harvey Nelson, Main Street Gourmet is a custom wholesale bakery providing frozen baked goods, including muffins, cookies, granola, brownies and bars, and other sweet goods to retail in-store bakery (“ISB”) and specialty foodservice customers across the United States. MSG operates out of an SQF certified 68,000 sq. foot manufacturing facility with approximately 160 employees in Akron, OH, and has been an important part of the community for more than 30 years.

Shore Capital is partnering with Mr. Marks and Mr. Nelson, the full MSG management team, and the previous majority shareholders, Clover Capital Partners, who helped guide the Company through a period of tremendous growth since partnering with the business in 2011. “We are proud of the custom and solutions-oriented bakery model we have built and scaled as a team and are excited to continue to serve our customers with a diverse range of high quality and differentiated products through a new phase of transformational growth. Our partnership with Shore Capital will allow us to accelerate our organic growth through expanding on our product capabilities, serving additional retail ISB and specialty foodservice customers and broadening our footprint by pursuing acquisitions with other differentiated bakeries in adjacent categories and channels,” said Mr. Nelson, CEO of MSG.

Shore plans to invest in the business development, sales & marketing, and production infrastructure to further enhance operations and explore opportunities for inorganic growth through acquisitions and organic growth through adjacent product lines, customers and distribution channels. “I have high aspirations for what we can collectively accomplish alongside Shore Capital and are excited to partner with a group that understands our value proposition as a custom, value-added supply chain partner. We continue to strive to be highly responsive with product development, able to commercialize new ideas in collaboration with our customers, and maintain flexibility to work with unique ingredients and processes,” added Mr. Marks, who formerly served alongside Mr. Nelson as co-CEO and will be serving on the Board of Directors under the partnership with Shore Capital.

“We could not be more excited to partner with the entire MSG team and look forward to creating a leading multi-regional bakery platform in the U.S. with a diverse range of high quality products, manufacturing capabilities and commitment to superior customer service,” said Richard Boos, Partner at Shore Capital and Chairman of MSG. “Harvey, Steve and Clover Capital have built an excellent business model focused on custom and solutions-driven products for its ISB and foodservice customers and we will work hard to collaborate with them to build on their success.”

About Shore Capital

Shore Capital is a Chicago-based private equity firm focused on microcap investments within the Healthcare and Food and Beverage industries. Shore supports management partners with capital, business development expertise, and industry knowledge to accelerate growth, fund acquisitions, and generate value to shareholders. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant growth potential, including organic and growth through industry consolidation. Shore has over $1 billion of equity capital under management through various investment vehicles. For more information, please visit: www.shorecp.com.

May 17, 2019 ‐ Shore Capital Partners (“Shore Capital” or “Shore”) is pleased to announce that it has formed Southern Ear, Nose, Throat and Allergy Partners (“SENTA”) and completed a strategic partnership with Northwest ENT and Allergy Center (“Northwest ENT” or the “Company”). Northwest ENT is a leading ear, nose and throat (“ENT”) and allergy services provider with seven locations including two affiliated ambulatory surgery centers in the Greater Atlanta, Georgia metro area. The Company offers comprehensive medical and surgical ENT and allergy services, including treatment for thyroid disorders, sinus conditions, ear pain, allergies, and throat disorders. Northwest ENT will continue to operate under its brand.

Shore Capital is partnering with Northwest ENT’s existing four partner physicians, Dr. Drew Locandro, Dr. Shatul Parikh, Dr. Ryan Kauffman and Dr. Avani Ingley, who have established a reputation for high quality medical and surgical specialty ENT and allergy care and lead a team of six doctors, one physician’s assistant, five audiologists and one nurse practitioner. Drew, Shatul, Ryan and Avani, and the Northwest ENT team have demonstrated impressive growth through the addition of new service lines and capabilities, recruiting talented physicians and specialists, and new center openings. “We are proud of the clinical foundation we have built as a team and are excited to continue to expand patient and referral partner access to our treatment and surgical services through a new phase of transformational growth. Our partnership with Shore Capital will allow us to accelerate our organic growth including opening new locations, hiring additional providers, and expanding our patient care and business support services while simultaneously pursuing affiliations with other leading practices,” said Dr. Parikh.

Shore plans to invest in infrastructure to further standardize operations and offer finance, accounting, compliance, marketing, human resources, IT and other support services to allow clinicians to focus on providing high quality ENT and allergy services. “Shore Capital is the ideal partner to help further our medical mission across a broader geographic reach and shares our commitment to leading clinical quality, operational excellence and increased patient access,” said Dr. Locandro. “I have high aspirations for what we can collectively accomplish and offer to our patients and their referring doctors,” commented Dr. Ingley. “We are thrilled about the partnership with Shore Capital and the deep healthcare experience and dedicated management and support services they bring to the table.”

SENTA and Northwest ENT will pursue affiliations with independent ear, nose and throat and stand alone allergy practices across the Southeast in order to build a leading network of doctors that maintains a patient-first culture with a clear focus on clinical care. “The partnership provides us with access to capital, administrative resources, operating expertise and strategic guidance while maintaining absolute focus on clinical quality as we seek to execute on our vision of building a leading ENT and allergy practice in the Southeast,” added Dr. Kauffman.

“We could not be more excited to partner with the entire Northwest ENT team and look forward to creating a leading ENT and allergy provider in the Southeast, while offering the highest level of support to our practices and clinicians,” said Chris Mioton, Chairman of SENTA. “Northwest ENT provides a solid foundation to build a best-in-class organization as SENTA seeks to be the partner of choice for practices throughout the Southeast who provide high quality patient care and desire a strategic partner to support their business operations and accelerate growth.”

This investment represents the eighth platform investment out of Shore Capital Partners Fund II, L.P., a $190 million investment vehicle raised in April 2017.

CHICAGO – November 1, 2017 – Shore Capital Partners (“Shore Capital” or “Shore”) is pleased to announce the recapitalization of Advanced Animal Hospital Group and Progressive Pet Animal Hospitals and merger of the respective businesses to form Midwest Veterinary Partners (“MVP” or the “Company”). The Company has 22 general practice veterinary clinics in Michigan, Wisconsin, and Illinois, and provides services to companion animals including vaccinations, surgery, wellness exams, oncology, ophthalmology, allergy treatment and dermatology. Financial terms of the transaction were not disclosed.

Shore has partnered with Dr. Vic Dhillon, owner of Advanced Animal Hospital Group, and Dr. Jeff Rothstein, owner of Progressive Pet Animal Hospitals, to pursue a consolidation of animal hospitals throughout the Midwest. Both Dr. Dhillon and Dr. Rothstein are entrepreneurial veterinarians with successful track records of acquiring and establishing high-quality animal hospitals.

“Since our founding, we have been firm believers that animals are not simply pets or property, they are members of the family, and we take great pride in helping to improve and maintain their health and overall well-being,” said Vic Dhillon, Advanced Animal Hospital Group founder. “As customized veterinary solutions have become more complex and demanding, we believe that collaborating with financial and strategic partners is beneficial for our customers and, of course, their beloved pets. With Shore Capital Partners’ investment and by joining forces with Progressive Pet Animal Hospitals, we will have the additional resources and capabilities to create a leading veterinary services company in the Midwest.”

“At Progressive Pet Animal Hospitals, we take great pride in offering extensive medical and preventative solutions for pets,” said Jeff Rothstein, Progressive Pet Animal Hospitals founder. “This investment and partnership will greatly expand our bandwidth and help grow our team of passionate and knowledgeable veterinary professionals. Both Shore Capital Partners and Advanced Animal Hospital Group are well-aligned with our mission and core values and we are delighted to now be operating under the Midwest Veterinary Partners brand.”

Shore plans to invest in infrastructure to standardize operations and provide support to MVP’s current and future clinics including centralized finance, accounting, human resources, IT, sales and marketing.

With pet ownership among U.S. households at an all-time high of 68%, and an increase in the average lifespan of pets, ownership costs have continued to rise and demand for veterinary services has increased. Veterinary service expenditures in the U.S. are expected to continue growing at more than 4% CAGR, surpassing $46 billion by 2021.

“Advanced Animal Hospital Group and Progressive Pet Animal Hospitals are terrific businesses that each have a reputation for providing high quality care and treatment for pets of all kinds, and that provide highly complementary services,” said Mike Cooper, a Partner at Shore Capital Partners. “Importantly, as pet ownership levels continue to increase, we believe this investment and merger represents a strategic opportunity to take advantage of a fragmented, yet growing market and to consolidate veterinary clinics throughout the Midwest. We are very pleased to partner with Vic, Jeff and their respective teams, and are eager to begin aggressively scaling this new company.”

This investment represents the fourth platform investment out of Shore Capital Partners Fund II, L.P., a $190 million investment vehicle raised in April 2017.

Katten Muchin Rosenman LLP provided legal counsel to Shore Capital Partners. Butzel Long provided legal counsel to the Advanced Animal Hospital Group and Progressive Pet Animal Hospitals.

About Shore Capital

Shore Capital is a Chicago-based private equity firm focused exclusively on microcap healthcare investments. Shore supports management partners with capital, business development expertise, and industry knowledge to accelerate growth, fund acquisitions, and generate value to shareholders. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant growth potential, including organic and growth through industry consolidation. Shore has approximately $350 million of equity capital under management through various investment vehicles including Shore Capital Partners Fund II, L.P. with $190 million of capital commitments. For more information, please visit: www.shorecp.com.

CHICAGO – November 2017 – Shore Capital Partners (“Shore Capital” or “Shore”) is pleased to announce the recapitalization of BrightView, LLC (“BrightView” or the “Company”). Headquartered in Cincinnati, the Company currently has 4 locations in Ohio and provides psychological, social and medical services, including medication assisted treatment, to individuals suffering from addiction. Financial terms of the transaction were not disclosed.

Shore has partnered with BrightView to increase access to effective comprehensive addiction treatment throughout Ohio and the surrounding states. Chad Smith, Chief Executive Officer (CEO), co-founded the Company in 2014 and has successfully led and grown the business, opening centers three and four this past summer. The Company plans to grow quickly to help address the immense unmet need for comprehensive medication assisted treatment across Ohio.

“We created BrightView with the goal of helping those in greatest need of addiction treatment services. Our comprehensive approach differentiates us from other providers and grants patients the greatest opportunity for a successful recovery,” stated Mr. Smith. “When we found Shore Capital, we discovered an ideal partner that would support our community center growth while never compromising on clinical quality.”

Shore plans to invest in infrastructure to standardize operations and provide support to BrightView’s current and future clinics including centralized finance, accounting, human resources, IT, development and marketing.

Rates of addiction and drug abuse, specifically opiates, are at an all-time high and have been rising steadily across all demographic groups and states since 2010. Drug overdoses are currently the leading cause of death in the U.S. for people under 50. In 2016, 11.8 million people reported misusing opioids. Further, 2.1 million individuals met the clinical criteria for having an opioid disorder. According to The National Survey on Drug Use and Health, as of 2015, only 11% of those suffering from a substance use disorder received treatment. BrightView hopes to help alleviate this treatment gap, by providing both high quality treatment and easily accessible care.

“BrightView’s differentiated model of care makes them the ideal partner as we set out to help more patients and communities in the Ohio Valley region,” stated John Hennegan, a Partner with Shore Capital. “Chad, his co-founders, and the entire BrightView team work each day to battle the biggest medical crisis of our time. We’re excited to utilize our experience in scaling leading healthcare service companies to assist them.”

This investment represents the third platform investment out of Shore Capital Partners Fund II, L.P., a $190 million investment vehicle raised in April 2017.

About Shore Capital

Shore Capital is a Chicago-based private equity firm focused exclusively on microcap healthcare investments. Shore supports management partners with capital, business development expertise, and industry knowledge to accelerate growth, fund acquisitions, and generate value to shareholders. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant growth potential, including organic and growth through industry consolidation. Shore has approximately $350 million of equity capital under management through various investment vehicles including Shore Capital Partners Fund II, L.P. with $190 million of capital commitments. For more information, please visit: www.shorecp.com.

Renton, WA – November 2017 – Navia Benefit Solutions, Inc. is pleased to announce that it has formed a growth partnership with Shore Capital Partners, a Chicago-based private equity firm focused on the healthcare industry. Founded in 1989, Navia is a leading third-party administrator (“TPA”) of consumer directed health benefit solutions serving clients nationwide.

Shore partnered with Hilarie Aitken and Matt Aitken who have led Navia through a period of tremendous growth since taking an active leadership role in 2003 following the passing of their father, Stan Aitken. Under the name Flex-Plan Services, Inc., Brothers Stan and Jim Aitken founded Navia in 1989 after seeing an opportunity to help employers administer tax-advantaged account based benefits such as Flexible Spending Accounts (“FSA”). Since then, Navia has evolved to offer other tax-advantaged benefits including Commuter and Transit Benefits, Health Savings Accounts (“HSA

"), Health Reimbursement Arrangements (“HRA”) and COBRA services.

“We believe Shore is the ideal partner to help facilitate growth through the expansion of our platform with new products and services over the coming years. We continue our commitment to providing the highest quality customer service and differentiated product offerings,” explained Ms. Aitken, CEO, who continues to lead the Company and will maintain a significant ownership position. “Shore’s support of strategic growth initiatives and proven expertise in partnering with other family-owned healthcare service businesses is impressive. We look forward to the opportunity to expand our platform with new products to new and existing customers.”

A highly experienced Board of Directors joins Navia in connection with the partnership to help execute Navia’s growth plan. The three independent Directors joining Navia include: (i) Greg Bell: experienced TPA operator and founder of First Benefit Corp. and HealthX, (ii) Jim Forrest: founding investor and former Director of MBI (now Alegeus), a leader in FSA payment processing technology, and (iii) Bill Clendenen: founder and former CEO of Health & Safety Institute, a compliance, safety and training services business that realized enterprise value growth of over 24% annually from 2006 to 2016 across three different private equity partnerships.

Ryan Kelley, a Partner at Shore Capital noted that, “We are excited to partner with a proven industry leader such as Navia. Supporting the growth of Navia by investing in products, people, and process to scale their unique TPA service offering is what we do best. After studying the broader payor services landscape, we believe that Navia represented an exceptional opportunity for Shore to grow a company well-positioned for an acceleration in consumer-directed healthcare. When you boil it down, Navia is helping consumers manage first dollar out-of-pocket healthcare expenses. The need for Navia’s services are only becoming more relevant given the rapid increase in health insurance premiums and rising healthcare deductibles pushed onto consumers.”

Navia represents the fifth platform investment out of Shore Capital Partners Fund II, L.P., a $190 million investment vehicle raised in April 2017.

About Shore Capital

Shore Capital Partners is a Chicago-based private equity firm focused exclusively on lower middle market healthcare investments. Shore supports management partners with capital, business development expertise, and industry knowledge to accelerate growth, and fund acquisitions. Shore has approximately $350 million of equity capital under management through various investment vehicles including the recently formed Shore Capital Partners Fund II, L.P. with $190 million of capital commitments.

ATLANTA, GA, August 2, 2017 – Shore Capital Partners ("Shore Capital"), a leading lower middle market healthcare private equity firm, is pleased to announce its portfolio company EyeSouth Partners (“EyeSouth” or the “Company”) has completed a strategic partnership with Georgia Retina, one of the largest retina medical practices in the Southeast.

“Our primary aim at Georgia Retina has always been to deliver exceptional medical and surgical retinal care combined with an outstanding patient experience,” said Dr. Michael Jacobson, who along with Dr. Scott Lampert founded Georgia Retina in 1994. “To further and build upon this mission in the rapidly changing healthcare environment, we have decided to enlist Shore Capital and EyeSouth as our partners to help us strengthen and expand our administrative and organizational structure.”

For over 20 years, Georgia Retina and its 13 board-certified ophthalmologists have offered first-class expertise in the treatment of diseases of the retina, macula, and vitreous to patients via 12 locations in the Atlanta metro area and throughout Georgia, including a strong commitment to providing care in underserved areas.

“Georgia Retina, EyeSouth and Shore Capital share similar cultural values,” said Dr. Atul Sharma, Managing Partner of Georgia Retina. “We are all committed to clinical excellence, increasing access to high quality care and providing our employees with opportunities for personal and professional growth. “We have a common vision of building a leading ophthalmology practice in the Southeast.”

“We are certain that Shore Capital and EyeSouth will enhance our ability to offer personalized cutting-edge care, the latest technologies, and expanding clinical research,” said Dr. Mark Rivellese of Georgia Retina. “We look forward to working together to better serve our patients throughout Georgia.”

Georgia Retina will continue to operate under its brand in the community with no changes to its staff, physicians or locations. Paul Lucas, CFO and Administrator of Georgia Retina, will continue to lead Georgia Retina as the President of EyeSouth’s Posterior (retina) Division.

“In the early days of forming EyeSouth, it was clear to us that Georgia Retina had a reputation in Georgia and the Southeast for leading clinical quality that aligned well with EyeSouth’s culture and vision,” said Justin Ishbia, Managing Partner at Shore Capital. “We are very excited to partner with the Georgia Retina physicians, Paul and their team as we continue to build a premier network of medical and surgical eye care services in Georgia and the Southeast.”

EyeSouth previously completed an affiliation with Georgia Eye Partners in February 2017. EyeSouth’s affiliate network consists of 26 doctors providing medical and surgical eye care services at 17 locations in Georgia.

About Georgia Retina

Headquartered in Atlanta, GA with 12 locations, Georgia Retina is one of the largest retina-only medical practices in the southeastern U.S. For over 20 years, Georgia Retina’s board-certified ophthalmologists have been offering first-class expertise in the treatment of diseases of the retina, macula and vitreous.

About EyeSouth Partners

Headquartered in Atlanta, GA, EyeSouth Partners (“EyeSouth”) is an eye care services organization committed to partnering with leading physicians to build a premier network of eye care services in Georgia and the Southeast. EyeSouth’s partner practices’ clinical mission is to provide high quality medical and surgical specialty eye care. EyeSouth supports its affiliated practices and physician partners with capital, administrative resources, operating expertise, and strategic guidance with an absolute focus on clinical quality and a patient-first culture. EyeSouth’s affiliate network consists of 26 doctors practicing at 17 locations in Georgia.

June 5, 2017 ‐ Shore Capital Partners (“Shore Capital” or “Shore”) is pleased to announce that it has completed a recapitalization of Behavioral Innovations (“BI” or the “Company”) and formed SCP Behavioral Innovations HoldCo, LLC. Behavioral Innovations provides center-based and in-home applied behavior analysis therapy (“ABA”), speech therapy (“SLP”) and occupational therapy (“OT”) services to children ages birth through 18 with autism spectrum disorder and other related developmental disabilities. In addition, BI offers adult services in community-based treatment settings. Behavioral Innovations has 13 centers in central and northern Texas and in-home services in the Oklahoma City, OK area.

Shore has partnered with Dan Nicholson, Executive Vice President, and co-founders Carla Edwards and Lori Russo, Board Certified Behavior Analysts (“BCBAs”). Ms. Edwards and Ms. Russo have been providing autism therapy services in Texas since 2000 and have established one of the largest providers in the state, representing a unique combination of best-in-class clinical quality and relative scale. Mr. Nicholson joined the Company in 2013 and has provided key leadership support and business development expertise amidst a period of robust growth.

“With a broad spectrum of high quality services helping children and adults with autism, Behavioral Innovations is the ideal partner for our growth investment,” said John Hennegan, Partner at Shore Capital and Chairman of SCP Behavioral Innovations HoldCo, LLC. “The formation of SCP Behavioral Innovations represents a unique opportunity to continue to recruit high caliber clinicians and expand access to treatment through new center openings and growth within the existing centers. We look forward to building a leading organization in the southwest, while continuing to provide the highest quality clinical care to our patients.”

“Shore Capital’s track record proves they’re the ideal partner as we accelerate our growth into new markets and expand our reach to serve more communities in Texas and Oklahoma,” said Dan Nicholson.

Behavioral Innovations plans to expand its presence through new center openings and select add-on acquisitions, while maintaining a therapist-driven culture with a clear focus on clinical care. As the prevalence of autism spectrum disorder increases and state insurance mandates improve access to therapy, it will be critical for high-quality providers like BI to expand and meet the growing demand.

“Shore Capital’s deep experience in multi-site healthcare services enables them to understand the unique needs of our business and provide the operating expertise, access to capital, and strategic guidance to help expand our footprint,” said Carla Edwards, who will continue in her role as Executive Director of Operations.

“Shore’s steadfast commitment to clinical quality confirmed we have identified the right partner for the next stage of growth,” added Lori Russo, who will continue to serve as Executive Director of Clinical Services.

This investment represents the first platform investment out of Shore Capital Partners Fund II, L.P., a $190 million investment vehicle raised in April 2017.

May 10, 2017 ‐ Shore Capital Partners, LLC (“Shore Capital” or “Shore”) is pleased to announce that IZI Medical Products, LLC (“IZI Medical” or “IZI”), its interventional products platform, has acquired the vertebroplasty family of products from Cook Medical (“Cook”). The acquired portfolio of products are commercially marketed under the highly regarded Duro-Ject® Osteo-Site®, Osteo-Force® and Vertefix® brands, consisting of needles, injectors and cements. These products are used in the growing market for treating vertebral compression fractures through a minimally invasive procedure.

“Cook has done an excellent job establishing these products as reliable, high-quality solutions for treating vertebral compression fractures and we have enjoyed working with them on this transaction,” said Greg Groenke, Chief Executive Officer, IZI Medical. “We are excited to increase the market penetration of these products through significant investment in a dedicated sales force, international distributor network, select product enhancements, and new product development, such as a unique and broader cement offering. IZI is also excited to be partnering with Dr. Kieran Murphy as part of the acquisition.”

Dr. Murphy is a highly regarded neuro-interventional radiologist who invented the primary needle and subsequently developed much of the vertebroplasty product line commercialized by Cook. Dr. Murphy will serve as a Key Opinion Leader and play an integral role in product development for IZI.

“This is a transformative acquisition for IZI, and is consistent with the strategy we developed when we partnered with Greg Groenke and the management team at IZI a year ago,” said Don Pierce, a Partner of Shore Capital Partners and Chairman of the Board of IZI. “This acquisition is an excellent fit with the broader strategy of building a leading platform serving the interventional radiology and oncology markets. This product family will extend IZI’s international sales reach and increase the depth of its product portfolio.”

Additionally, and concurrent with the product family acquisition, Michael Shaffer will be transitioning from Shore Capital Partners to IZI to serve as its Chief Financial Officer, where he will drive the integration of this acquisition and subsequent investments.

Spinal compression fractures are often caused by osteoporosis, a disease of low bone strength that affects an estimated 10 million Americans, resulting in an estimated 700,000 spinal fracture cases annually that can cause disabling pain, height loss, balance difficulties and a decreased quality of life. In the U.S., approximately 50 percent of women and 25 percent of men over the age of 50 will experience an osteoporosis fracture in their lifetime.

March 14, 2017 – Shore Capital Partners (“Shore Capital” or “Shore”) is pleased to announce that it has formed EyeSouth Partners, LLC and completed a strategic partnership with Georgia Eye Partners (“Georgia Eye” or the “Company”). Founded in 1999 by Dr. Eugene Gabianelli, Georgia Eye is a leading eye care practice with four locations in the Atlanta, Georgia area. The Company offers medical and surgical specialty eye care services, including treatment for cataracts, corneal disease, refractive surgery, glaucoma, and oculoplastics through OPAL Aesthetics.

Shore Capital is proud to partner with Georgia Eye’s three partner physicians, Dr. Eugene Gabianelli (“Gino”), Dr. Andrew Feinberg (“Andrew”), and Dr. Parul Khator (“Parul”), who have established a reputation for high quality medical and surgical specialty eye care and lead a team of eight ophthalmologists and five optometrists. Gino, Andrew, Parul, and the Georgia Eye team have demonstrated impressive growth through the addition of new service lines, recruiting talented physicians and specialists, and new center openings and practice affiliations.

“We are tremendously proud of what our team has built over the past 17 years and appreciative of the trust our patients and referral partners place in us. We believe Shore Capital is the ideal partner to help facilitate our next phase of transformational growth and shares our commitment to leading clinical quality, operational excellence, a great workplace culture for our team members, and increased patient access,” said Dr. Gabianelli, founding physician, who will continue to lead the Company’s clinical team as Chief Medical Officer.

“I’ve been impressed by Shore’s energy, support of strategic growth initiatives, and proven expertise in the multi-site healthcare services space,” said Dr. Feinberg. “The partnership provides us with access to capital, administrative resources, operating expertise and strategic guidance while maintaining absolute focus on clinical quality as we seek to execute on our vision of building a leading practice in the Southeast,” said Dr. Khator.

“We could not be more excited to partner with Gino, Andrew, Parul and their team and look forward to creating a leading eye care provider in the Southeast, while providing the highest level of support to our practices and clinicians,” said Justin Ishbia, Managing Partner at Shore Capital and Chairman of EyeSouth Partners. “We are confident the industry trends will continue to support expansion thereby enhancing patient access and creating additional opportunities for our team members. Georgia Eye Partners provides an excellent foundation to build a best-in-class organization.”

Shore plans to invest in infrastructure to further standardize operations and centralize the finance, accounting, human resources, and IT functions to allow the clinicians to focus on providing high quality eye care services. Shore will be adding additional executive team members around current Chief Executive Officer Scott Bullock, who joined the Company in 2010 and has overseen a period of more than three times revenue growth.

The Company will pursue affiliations with independent eye care practices in order to build a group of clinicians that maintains a patient-first culture with a clear focus on clinical care.

EyeSouth Partners represents the eighth platform investment out of Shore Capital Partners Fund I, L.P., a $112.5 million investment vehicle raised in May 2014.

January 20, 2017 – Shore Capital Partners (“Shore Capital” or “Shore”) today announced that it has completed a growth investment in Argentum Medical, LLC and certain assets of Cura Surgical, Inc. (“Argentum” or the “Company”). Founded in 2001 and located in Geneva, IL, Argentum manufactures and sells innovative wound care products across a wide number of clinical applications, including the Silverlon® (“Silverlon”) brand, its rapidly-growing, proprietary range of silver-based antimicrobial products.

The core platform technology in Silverlon is a uniquely designed silver-plated nylon matrix that provides the powerful antimicrobial properties of silver ions in the dressing without staining the skin and without increasing bioburden. Silverlon dressings are used today by surgeons and other healthcare professionals around the world on surgical wounds, burns, chronic wounds, IV catheter-related wounds, and for negative pressure wound therapy.

Following Argentum’s history of robust research and development support, in 2015, the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) awarded Argentum a multi-year contract up to $16.5 million to conduct research to support new Silverlon indications. In addition, BARDA selected Silverlon from a broad range of wound care products for inclusion on an annual basis in the Strategic National Stockpile (“SNS”). The SNS is intended to offer products that have the potential to eliminate resource-intensive steps, shorten hospital stays and improve patient outcomes in the event of a disaster.

“Shore Capital is the ideal partner for Argentum as the Company continues to move into a rapid growth phase,” said Raul Brizuela, CEO of Argentum, who will continue to lead the Company’s management team. “I’ve been impressed by Shore’s shared vision with the Company, support of strategic growth initiatives, and proven expertise in the healthcare space. We are excited for the partnership and look forward to accelerating growth of the Silverlon brand worldwide.”

Shore will focus on expanding sales and marketing efforts with U.S. hospitals, burn and wound care centers, as well as with international customers. Additionally, the Company will pursue an aggressive acquisition strategy to broaden its advanced wound care and infection prevention portfolio. Shore will be supplementing the incumbent management team with an experienced board of directors to help support these efforts. The partnership’s goal is to create a leading advanced wound care platform by further penetrating the U.S. market, expanding into additional clinical uses, and pursuing targeted new product innovation.

“We are thrilled to partner with Raul and the Argentum team during this exciting stage of growth for the business,” said Don Pierce, Partner at Shore Capital. “Advanced wound care products, specifically anti-microbial dressings, will continue to provide significant value to hospitals as they strive to improve quality and patient outcomes, decrease costs and mitigate risk. Argentum and Silverlon are uniquely positioned to provide comprehensive solutions for improved wound care management. We look forward to working with the Argentum team to build a market leader in the U.S. and internationally.”

Argentum represents the seventh platform investment out of Shore Capital Partners Fund I, L.P., a $112.5 million investment vehicle raised in May 2014. Argentum was advised by The Walden Group during the transaction.

October 3, 2016 – Shore Capital Partners ("Shore Capital"), a healthcare-focused private equity firm, today announced the sale of ClearPath Diagnostics ("ClearPath"), a leading provider of laboratory diagnostic services in the Northeastern United States, to Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the world's leading healthcare diagnostics company.

Shore Capital partnered with ClearPath's founding pathologists, Dr. Michael Jozefczyk and Dr. Michael Mazur, to drive the company's expansion beyond the local Syracuse, New York market. Together, Shore Capital and ClearPath executed a growth strategy that extended the company's geographic reach to four states and expanded the service menu to include new cutting-edge tests. The growth was driven by organic initiatives as ClearPath expanded the sales force from one professional to a team of nine highly trained business development experts and implemented LEAN processes that ensured best-in-class turnaround times.

ClearPath's co-founder and President, Michael Jozefczyk stated,

"Shore Capital was the perfect partner to guide ClearPath through a period of transformational growth. Their commitment to clinical quality combined with deep business development expertise allowed ClearPath to thrive during a difficult period in the diagnostic lab industry. With Shore Capital's assistance, we successfully expanded into three new states across the Northeast and our revenue growth outpaced industry averages by more than 10x. The commitment to growth combined with sophisticated metric management techniques allowed us to become the leading independent provider of cancer testing services in the Northeast.""The success of this partnership is a testament to the hard work of the ClearPath team and further validation of Shore Capital's model of partnering with influential clinicians to grow local businesses into regional leaders," said Justin Ishbia, Managing Partner of Shore Capital and Chairman of ClearPath Diagnostics. "We are pleased with the outcome of this partnership and believe that ClearPath is well positioned to continue growing as a leader in the field of cancer diagnostics.""LabCorp is excited to both continue its commitment to the upstate New York medical communities and for the potential to grow career opportunities in the entire region over time," said William Haas, LabCorp Senior Vice President and Co-leader of LabCorp Diagnostics. "The combination of LabCorp's comprehensive women's health service offering coupled with the local expertise of the ClearPath professional team will be an unmatched blend of value and quality to our Obstetric and Gynecologic customers and patients."

The transaction closed on October 3, 2016. Terms of the transaction were not disclosed. Winston & Strawn LLP served as legal advisor to ClearPath on the transaction.

About ClearPath

Incorporated in 2002, ClearPath's founding pathologists have been practicing in Upstate New York since 1975. By combining cytology and pathology with comprehensive administrative support, ClearPath Diagnostics offers clinicians an unsurpassed resource for anatomic pathology outreach services in New York, Connecticut, New Jersey, Pennsylvania and beyond. www.clearpathdiagnostics.com

August 23, 2016 – Shore Capital Partners (“Shore Capital”) a healthcare-focused private equity firm, is pleased to announce the sale of Fast Pace Urgent Care (“Fast Pace”), a leading provider of urgent care services throughout rural Tennessee and Kentucky, to Revelstoke Capital Partners.

In December 2012, Shore Capital partnered with Fast Pace founders, Stan Bevis and Reams Powers, to help grow their initial seven urgent care locations. Shore Capital and Fast Pace together executed an accelerated growth plan and expanded the business from seven to 36 clinics in approximately three and a half years. The growth came primarily through de novo expansion as the company opened 26 new locations and acquired three locations. Five incremental locations are scheduled to open later this year. In addition to geographic expansion, Fast Pace increased corporate infrastructure while implementing operational efficiencies to become a recognized leader in the delivery of urgent care and primary care services.

Fast Pace’s co-founder and CEO, Stan Bevis, stated, “Shore Capital has been the ideal partner to support our rapid growth due to their expertise in de novo site selection, add on acquisitions, metric management and ability to help scale the company as it grew from 50 to 700 employees. With the guidance of the Shore team and Fast Pace board, we were able to exceed our growth projections, resulting in yearly patient visits increasing from 40,000 in 2012 to approximately 400,000 today. The success and rapid growth over the past three and a half years is attributable to our successful partnership with Shore and an outstanding management team. We are excited to continue to develop the business and expand to additional communities.”

“The Fast Pace and Shore Capital partnership was a successful combination due to the strong alignment between the founders, investors and other stakeholders,” said Ryan Kelley, a Partner with Shore Capital and Chairman of Fast Pace. “We are very pleased with the outcome and believe Fast Pace is well positioned to continue its growth as a leader in the urgent care industry.”

Houlihan Lokey served as financial advisor and Winston & Strawn served as legal advisor to Fast Pace on the transaction. Ropes & Gray LLC served as legal advisor to Revelstoke Capital Partners.

About Fast Pace

Fast Pace was founded in 2009 and is the largest independent provider of urgent care and primary care services in Tennessee. Fast Pace is headquartered in Brentwood, TN and provides convenient and affordable healthcare services to rural markets throughout Tennessee and Kentucky. Fast Pace provides treatment for a wide range of illnesses, injuries, and common conditions, in addition to diagnostic and screening services. www.fastpaceurgentcare.com/

July 21, 2016 – Shore Capital Partners announced an investment in AlphaVista Services. AlphaVista provides speech language pathology, occupational therapy, special education, school psychology and related services to a variety of public school districts and private learning centers.

May 3, 2016 – Shore Capital Partners announced an investment in IZI Medical Products, a manufacturer of medical consumable accessories used in radiology, radiation therapy and image guided surgery procedures.

November 2, 2015 – Shore Capital Partners announced an investment in Specialdocs Consultants, specialists in converting traditional primary care physicians to a personalized or concierge medicine model.

October 15, 2015 – Shore Capital Partners announced an investment in Shippert Medical, a manufacturer of medical and surgical supplies.

August 21, 2015 – Shore Capital Partners announced an investment in Florida Autism Center, a provider of center-based applied behavior analysis (“ABA”) treatment services to children diagnosed with Autism Spectrum Disorder (“ASD”).

April 7, 2015 – Shore Capital Partners announced an investment in Great Lakes Dental Partners, four general practice dental offices located in Chicago, IL. Click here to learn more.

February 21, 2011 – Shore Capital Partners announced the opening of a new Sirona Infusion branch in Albuquerque, NM.

September 19, 2011 – Shore Capital Partners announced an investment in ClearPath Diagnostics, a leading anatomic pathology practice and laboratory in New York.

January 6, 2012 – Shore Capital Partners announced an investment in HomeCare IV, a leading home infusion provider in Central Oregon.

April 1, 2012 – Shore Capital Partners announced the opening of a new Sirona Infusion branch in Denver, CO.

May 2, 2012 – Shore Capital Partners announced an investment in Excel Rehabilitation Services and Michigan Rehabilitation Specialists, both leading providers of outpatient physical therapy throughout Michigan.

October 15, 2012 – Shore Capital Partners announced the opening of a new Access I.V. branch in Sacramento, CA.

December 28, 2012 – Shore Capital Partners announced an investment in Fast Pace Urgent Care, a leading provider of urgent care services throughout Tennessee.

June 11th, 2013 – Shore Capital Partners announced an investment in InfuSource, a leading home infusion provider in Northern California.

June 25th, 2013 – Shore Capital Partners announced an investment into Quantum Physical Therapy and Michigan Rehabilitation Specialists of Davison which are leading physical therapy providers in Michigan.

August 5, 2013 – Shore Capital Partners (“Shore”), a healthcare-focused private equity firm, is pleased to announce the sale of its physical therapy portfolio company SCP Physical Therapy to ATI Physical Therapy, a nationally recognized comprehensive rehabilitation provider, specializing in research-based physical therapy, sports medicine, work conditioning/hardening, functional capacity assessments, aquatic health, hand therapy and women’s health.

In May 2012, Shore acquired and merged two physical therapy companies, Michigan Rehabilitation Specialists (“MRS”) and Excel Rehabilitation Services (“Excel”) into SCP Physical Therapy. Together, Shore and the company’s management expanded the company’s presence in Michigan from 17 clinics to 33 clinics through aggressive new clinic growth and two add-on acquisitions. Additionally, Shore and its operating partners provided operational expertise to develop and implement sophisticated metric management tools to improve and enhance the operations of the business.

“We are pleased to have supported SCP Physical Therapy’s development into the leading independent provider of outpatient physical therapy in Michigan,” said Justin Ishbia, Founder and Managing Partner of Shore Capital Partners. “This transaction validates our model of partnering with strong clinicians to grow local businesses into regional leaders.” “When we invested in MRS and Excel, we saw a tremendous opportunity to build on the companies’ clinical expertise and strong reputation in Michigan,” said Joseph Mooney, a Shore Capital Operating Partner who served as the full-time Chief Marketing Officer for SCP Physical Therapy. “We are pleased that the combination of management’s clinical expertise and Shore’s operational and financial support allowed the company to aggressively expand its footprint in Michigan and become an attractive strategic acquisition for ATI Physical Therapy.”

The transaction closed on August 5, 2013. Terms of the transaction are not disclosed. Winston & Strawn, LLP provided legal counsel to Shore.

This is the first realization for Shore, which was founded in 2009. Shore has completed 11 investments across the physical therapy, home infusion, lab services, and urgent care sectors.

About Michigan Rehabilitation Specialists and Excel Rehabilitation Services

Established in 1999 and 1994, respectively, MRS and Excel provide physical and occupational therapy for orthopedic injuries, work related injuries, sports injuries and various neurological and neuromuscular conditions. The combined companies operate 33 locations throughout Michigan. For additional information, please visit the company website at www.mrspt.com.

September 17, 2013 – Shore Capital Partners announced an investment in RapidCare Clinic, a leading provider of urgent care services throughout Tennessee.

November 25, 2013 – Shore Capital Partners (“Shore”), a healthcare-focused private equity firm, is pleased to announce the sale of its home infusion therapy portfolio company, SCP Specialty Infusion, to AxelaCare Health Solutions, a leading provider of specialty home infusion services specializing in IVIg (immune globulin).

In November 2009, Shore partnered with Chris York, CEO, and Mitch Friedman, CFO, long time home infusion industry veterans, to complete a roll-up strategy in the space. In July 2010, the management team and Shore made their platform investment in Arizona-based Sirona Infusion, LLC. Over the next three and a half years, Shore and management completed three add-on acquisitions and built three de novo pharmacies to become one of the largest privately-owned home infusion platforms in the country. Shore and management integrated these distinct and regionally diverse companies by standardizing operations with weekly and monthly metric management, a unified IT platform, and consolidated HR, corporate compliance, accounting and finance.

“We are pleased to have partnered with management to build SCP Specialty Infusion into one of the preeminent home infusion providers in the country,” said Justin Ishbia, Founder and Managing Partner of Shore Capital Partners. “Further, the successful execution of our value creation plan has allowed us to complete the sale of SCP Specialty Infusion on favorable terms for our investors.”

“Over the last three and a half years, we’ve built a company on the model of putting the patient first,” said Chris York, CEO of SCP Specialty Infusion. “We are confident that this model, combined with aggressive business development and an intense focus on metric management, enabled us to build a scarce asset in the home infusion industry. Shore’s operational oversight and financial support coupled with management’s industry expertise were highly complementary and helped facilitate the platform’s growth.”

The transaction closed on October 31, 2013. Terms of the transaction are not disclosed. Bass, Berry & Sims PLC provided legal counsel to SCP Specialty Infusion.

The sale of SCP Specialty Infusion marks the second successful realization for Shore, which was founded in 2009. In August, the firm announced in a press release the sale of its physical therapy platform, SCP Physical Therapy, to ATI Physical Therapy. Shore has completed 11 investments across the home infusion, lab services, physical therapy, and urgent care sectors.

About SCP Specialty Infusion

SCP Specialty Infusion, founded in 2010 with the acquisition of Sirona Infusion, LLC, is the premier provider of acute home infusion services in the Western U.S. Its network of pharmacies, infusion centers, and nursing staff spans Arizona, New Mexico, California, Colorado, and Oregon. Therapies delivered include the full spectrum of acute and chronic infusion therapies including anti-infective, oncolytic, total parenteral nutrition (TPN), cardiac, hydration, and other intravenously delivered medicines.

May 21, 2014 – Shore Capital Partners announced an investment in Cumberland Therapy Services and MyTherapyCompany, both leading providers of pediatric therapy services.

October 6, 2014 – Shore Capital Partners announced an investment in Southern Veterinary Partners, three general practice animal hospitals that provide veterinary services in the Southeast United States.

February 20, 2015 – Shore Capital Partners announced an investment in Summit Medical, a medical device manufacturer located in St. Paul, MN.

February 25, 2015 – Shore Capital Partners announced an investment in Valleydale Animal Clinic, a full service animal hospital that provide veterinary care in Birmingham, AL.